Wave Life Sciences (WVE) Other Accumulated Expenses (2014 - 2017)
Wave Life Sciences' (WVE) quarterly Other Accumulated Expenses came in at $156000.0 in Q4 2017, down 83.54% YoY from $948000.0 in Q4 2016, and down 83.54% on a QoQ basis from $948000.0 in Q4 2016.
Analysis
Wave Life Sciences (WVE) Other Accumulated Expenses (2014 - 2017) Analysis & Trends
Wave Life Sciences (WVE) has 4 years of Other Accumulated Expenses data on file, last reported at $156000.0 in Q4 2017.
- Quarterly Other Accumulated Expenses fell 83.54% year-over-year to $156000.0 in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $156000.0 (down 83.54% YoY) and the FY2017 annual result came in at $156000.0, down 83.54% from the prior year.
- Other Accumulated Expenses fell to $156000.0 in Q4 2017, from $948000.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $948000.0 in Q4 2016 to a low of $156000.0 in Q4 2017.
- A 4-year average of $408000.0 and a median of $353000.0 in 2015 frame the typical range for Other Accumulated Expenses.
- Annual changes were most pronounced in 2016 — Other Accumulated Expenses soared 168.56% — and 2017, when it sank 83.54%.
- Tracing WVE's Other Accumulated Expenses over 4 years: stood at $177000.0 in 2014, then jumped by 99.44% to $353000.0 in 2015, then soared by 168.56% to $948000.0 in 2016, then slumped by 83.54% to $156000.0 in 2017.
- The last three Other Accumulated Expenses figures came in at $156000.0 (Q4 2017), $948000.0 (Q4 2016), and $353000.0 (Q4 2015), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Wave Life Sciences | 994.54 Mn | 626.53 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2017 | 156,000.00 |
| Dec 31, 2016 | 948,000.00 |
| Dec 31, 2015 | 353,000.00 |
| Sep 30, 2015 | 406,000.00 |
| Dec 31, 2014 | 177,000.00 |